BusinessWire

January 17, 2021 Off

JS Bio and Etta Biotech Advancing Strategic Partnership

THOUSAND OAKS, Calif. & SHANGHAI–(BUSINESS WIRE)–#CellElectroporation–Jianshun Biosciences Co., Ltd. (“JS Bio”) recently announced its strategic partnership with Etta Biotech Co.,…

January 17, 2021 Off

JS Bio and Etta Biotech Advancing Strategic Partnership

By BusinessWire

THOUSAND OAKS, Calif. & SHANGHAI–(BUSINESS WIRE)–#CellElectroporation–Jianshun Biosciences Co., Ltd. (“JS Bio”) recently announced its strategic partnership with Etta Biotech Co.,…

January 16, 2021 Off

Servier announce updated overall survival results of exploratory TASCO1 phase II study of LONSURF® + bevacizumab in a first-line setting for patients with unresectable mCRC non-eligible for intensive therapy

By BusinessWire

PARIS–(BUSINESS WIRE)–Servier announced today updated results from the exploratory phase II TASCO1 study evaluating LONSURF® (trifluridine/tipiracil) + bevacizumab and capecitabine…

January 16, 2021 Off

Servier announce updated overall survival results of exploratory TASCO1 phase II study of LONSURF® + bevacizumab in a first-line setting for patients with unresectable mCRC non-eligible for intensive therapy

By BusinessWire

PARIS–(BUSINESS WIRE)–Servier announced today updated results from the exploratory phase II TASCO1 study evaluating LONSURF® (trifluridine/tipiracil) + bevacizumab and capecitabine…

January 16, 2021 Off

Servier announce updated overall survival results of exploratory TASCO1 phase II study of LONSURF® + bevacizumab in a first-line setting for patients with unresectable mCRC non-eligible for intensive therapy

By BusinessWire

PARIS–(BUSINESS WIRE)–Servier announced today updated results from the exploratory phase II TASCO1 study evaluating LONSURF® (trifluridine/tipiracil) + bevacizumab and capecitabine…

January 16, 2021 Off

Servier announce updated overall survival results of exploratory TASCO1 phase II study of LONSURF® + bevacizumab in a first-line setting for patients with unresectable mCRC non-eligible for intensive therapy

By BusinessWire

PARIS–(BUSINESS WIRE)–Servier announced today updated results from the exploratory phase II TASCO1 study evaluating LONSURF® (trifluridine/tipiracil) + bevacizumab and capecitabine…

January 16, 2021 Off

ENHERTU® Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Advanced Gastric Cancer

By BusinessWire

First HER2 directed medicine approved for patients with gastric cancer in a decade TOKYO & MUNICH & BASKING RIDGE, N.J.–(BUSINESS…

January 16, 2021 Off

ENHERTU® Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Advanced Gastric Cancer

By BusinessWire

First HER2 directed medicine approved for patients with gastric cancer in a decade TOKYO & MUNICH & BASKING RIDGE, N.J.–(BUSINESS…

January 16, 2021 Off

ENHERTU® Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Advanced Gastric Cancer

By BusinessWire

First HER2 directed medicine approved for patients with gastric cancer in a decade TOKYO & MUNICH & BASKING RIDGE, N.J.–(BUSINESS…

January 16, 2021 Off

ENHERTU® Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Advanced Gastric Cancer

By BusinessWire

First HER2 directed medicine approved for patients with gastric cancer in a decade TOKYO & MUNICH & BASKING RIDGE, N.J.–(BUSINESS…